High-dose Zevalin with stem cell transplant may benefit NHL patients

10/21/2008 | RTT News

A study showed that 83% of patients with relapsed/refractory or high-risk aggressive non-Hodgkin's lymphoma were disease-free 30 months after receiving high-dose Zevalin and undergoing a tandem stem cell transplant. The findings add to evidence that "Zevalin at higher than FDA approved doses with a stem cell rescue may provide an added clinical benefit" when combined with standard chemotherapy, a company official said.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT